Episode list

A controlled trial gives Vtesse the best shot at getting VTS-270 approved by regulatory agencies such as FDA and EMA. In a controlled trial, the resulting data from the trial is stronger, and thus more likely to demonstrate VTS-270's efficacy. Furthermore, a controlled study will allow the benefits/risks of VTS-270 to be more precisely understood.

Not only would a clinical trial mean getting closer to regulatory approval, it would also allow researchers to take a big first step toward refining VTS-270 and making it even more optimized for treating Niemann-Pick Type C.

Ben is the President and Chief Executive Officer of Vtesse. He has over 25 years of experience in drug development, including participating in the development of the first publicly available vaccine for H1N1 (swine flu). He now brings his expertise to parents and doctors in the fight against NPC. Ben and his wife of over 30 years take great pride in their two children. He enjoys bicycling with his wife and cooking.

Ravi is the Chief Business Officer of Vtesse. Although he was trained as a scientist, his extensive experience in corporate strategy, partnering, collaboration and implementation gives Vtesse the business know-how it needs to make things happen in the fight against NPC. He has been married for 12 years and has two sons.

"Our promise is to think about the kids first, to think outside the box where we can, and to deliver on our promises."

The chance to help children with no other solutions motivates Ben to get approval for VTS-270.

While Ben has worked on many drug-development teams, he looks forward to helping the NPC community in a direct and personal way.

Ravi feels personal responsibility to use the experience he has in drug development to help these kids and families.

Ben recalls the nervousness and fear he felt when his daughter went through a simple heart surgery.

As the parent of a 2-year-old and a newborn, Ravi finds great pleasure in seeing the world through the eyes of his son.